YY1 promotes HDAC1 expression and decreases sensitivity of hepatocellular carcinoma cells to HDAC inhibitor

Sheng Dong; Xiang Ma; Zusen Wang; Bing Han; Hao Zou; Zehua Wu; Yunjin Zang; Likun Zhuang

doi:10.18632/oncotarget.17196

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

YY1 promotes HDAC1 expression and decreases sensitivity of hepatocellular carcinoma cells to HDAC inhibitor

Sheng Dong _, Xiang Ma, Zusen Wang, Bing Han, Hao Zou, Zehua Wu, Yunjin Zang and Likun Zhuang

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:40583-40593. https://doi.org/10.18632/oncotarget.17196

Metrics: PDF 1986 views | HTML 2219 views | ?

Abstract

Sheng Dong1, Xiang Ma1, Zusen Wang1, Bing Han1, Hao Zou1, Zehua Wu1, Yunjin Zang2 and Likun Zhuang2

1Department of Hepatobiliary and Pancreatic Surgery, The Affiliated Hospital of Qingdao University, Qingdao, 266003, China

2Institute of Transplantation Science, The Affiliated Hospital of Qingdao University, Qingdao, 266003, China

Correspondence to:

Likun Zhuang, email: [email protected]

Yunjin Zang, email: [email protected]

Keywords: YY1, HDAC1, HDAC inhibitor, HCC, drug sensitivity

Received: February 20, 2017 Accepted: April 05, 2017 Published: April 18, 2017

ABSTRACT

YY1 is a DNA-binding transcription factor and reported to be involved in cancer progression. Histone deacetylase inhibitor (HDACi) could inhibit proliferation and promote apoptosis of Hepatocellular carcinoma (HCC) cells. However, it is unclear about the roles of YY1 in the sensitivity of HCC cells to HDACi. In this study, firstly, we identified two drug-response profiles to HDACi in HCC cell lines, while our results showed that HDAC1 expression was positively correlated with YY1 in HCC cell lines and primary tumor tissues. Secondly, YY1 decreased the sensitivity of HCC cells to HDACi in vitro and in vivo. Furthermore, we found that YY1 promoted HDAC1 expression by binding to its promoter, while HDAC1 in turn up-regulated the expression of YY1. In conclusion, our results showed that YY1 could reduce the sensitivity of HCC cells to HDACi and might be a potential therapeutic target in HCC.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 17196

Publication Alerts

Research Papers:

YY1 promotes HDAC1 expression and decreases sensitivity of hepatocellular carcinoma cells to HDAC inhibitor

Abstract